Performance characteristics of the new ARCHITECT Toxo IgG and Toxo IgG Avidity assays |
| |
| Authors: | Eva Sickinger Françoise Gay-Andrieu Gesa Jonas Jan Schultess Myriam Stieler Darwin Smith Michael Hausmann René Stricker Reto Stricker Jens Dhein Hans-Bertram Braun |
| |
| Institution: | 1. Abbott GmbH & Co. KG, Max-Planck-Ring 2, D-65205 Wiesbaden-Delkenheim, Germany;2. Laboratoire de Parasitologie, CHU de Nantes, 44093 Nantes Cedex, France;3. Abbott Diagnostics, Abbott Park, IL 60064, USA;4. Dianalabs SA, Geneva 1205, Switzerland |
| |
| Abstract: | The ARCHITECT Toxo IgG and IgG Avidity assays have been developed as a fully automated panel for immune status determination and acute infection exclusion. Resolved relative specificity and sensitivity of the ARCHITECT Toxo IgG assay were 99.6% (1359/1365) and 99.7% (1096/1099) as determined on pregnant females, blood donor, and diagnostic specimens. Seroconversion sensitivity of the ARCHITECT assay was comparable with the AxSYM Toxo IgG assay. The ARCHITECT Toxo IgG Avidity assay detected 100.0% (124/124) of acute phase specimens (<4 months after infection) as low avidity, whereas the Vidas Toxo IgG Avidity assay detected 98.9% (89/90) as low avidity. In summary, the ARCHITECT Toxo IgG assay, using recombinant antigens, showed excellent specificity and sensitivity for acute phase as well as past infection specimens. The ARCHITECT Toxoplasmosis panel can be reliably used to rule out acute Toxoplasma gondii infection in pregnant women. |
| |
| Keywords: | Toxoplasmosis Congenital infection Recombinant antigens Toxo IgG and avidity Acute and past infection |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
